Feeds:
Posts
Comments

Archive for the ‘Personalized and Precision Medicine & Genomic Research’ Category


The 13th Annual Personalized Medicine Conference: “From Concept to the Clinic”, November 14 – 16, 2017, Joseph B. Martin Conference Center, Harvard Medical School, 77 Avenue Louis Pasteur, Boston

Reporter: Aviva Lev-Ari, PhD, RN

 

The 13th Annual Personalized Medicine Conference will blend an exploration of all the issues facing personalized medicine with practical insights from both clinical experts and patients on how to move evolving concepts into the clinic. Among other topics, the program will cover value frameworks and pharmaceutical pricing, the implications of gene therapy and gene editing, the Trump administration’s perspectives on personalized medicine, and the role of big data.

The dialogue at the conference shapes the community’s agenda and guides the Coalition’s work. Anyone with an interest in the field is welcome to participate.

 

SOURCE

From: <pmc@personalizedmedicinecoalition.org>

Date: Monday, March 13, 2017 at 10:19 AM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: The 13th Annual PM Conference: “From Concept to the Clinic”

Advertisements

Read Full Post »


Precision Medicine Market size worth $87.7BIL by 2023

 Article Publication Request by

Jui Kate | SEO Analyst

Global Market Insights

E-mail: jui.k@gminsights.com | Web: www.gminsights.com 

Published Date: July 25, 2016   Author: Global Market Insights, Inc.

Precision Medicine Market size is expected to reach USD 87.79 billion by 2023; as per a new research report by Global Market Insights, Inc.
Increasing demand for personalized medicine specifically in cancer treatments and advancements in new healthcare technologies will drive precision global medicine market size. Favorable government regulations and standards will help sustain revenue growth.
The individualized diagnosis approach has dramatically improved owing to large-scale biologic database development, efficient methods for patient characterization, and computational tools to analyze large data sets. Emphasizing the need for public health database, The White House dedicated USD 55 million for creation of its largest database ‘Precision Medicine Initiative’ (PMI).

 

 Request Sample Buy NowInquiry Before Buying

 

Recent research advances have helped expand benefits to various aspects of healthcare by enabling better understanding of disease mechanisms, assessment of disease risks and prediction of optimal therapy. A large number of investments in diagnostic research will further accelerate the shift from treatment to preventive medicine in healthcare.
Gene sequencing market size was over USD 8 billion in 2015. Post announcement of the PMI, FDA has recently issued draft guidelines on next generation sequencing-based tests to develop a new kind of healthcare that takes into account individual differences in people’s genes, environments and lifestyles.
Browse key industry insights spread across 94 pages with 85 market data tables & 62 figures & charts from the report, “Precision Medicine Market Size By Technology (Big Data Analytics, Gene Sequencing, Drug Discovery, Bioinformatics, Companion Diagnostics), By Application (Oncology, CNS, Immunology, Respiratory), Industry Analysis Report, Regional Outlook (U.S., Canada, Germany, UK, France, Scandinavia, Italy, Japan, China, India, Singapore, Mexico, Brazil, South Africa, UAE, Qatar, Saudi Arabia), Application Potential, Price Trends, Competitive Market Share & Forecast, 2016 – 2023” in detail along with the table of contents:

https://www.gminsights.com/industry-analysis/precision-medicine-market
Key insights from the report include:

  • Drug discovery technology contributed over USD 9 billion to the global precision medicine market size in 2015, and is estimated to expand at 8.3% CAGR from 2016 to 2023. NGS and other such technologies will open new opportunities for industry participants. Regulation of NGS based test development will help create regulatory processes for genetic test development and application.
  • The global companion diagnostics market is predicted to reach USD 17 billion by 2023. It plays a significant role in development of targeted drugs, thus speeding up the move towards more precise and individualized pharmacotherapy.
  • Oncology application was over 30% of the precision medicine market share in 2015. There have been significant developments taken place across the globe in the area of breast cancer and other related cancers. Predictive biomarkers in lung cancer therapy targets receptors such as c-ros oncogene 1 receptor tyrosine kinase (ROS1), Epidermal Growth Factor Receptor (EGFR), Immune Checkpoints, and Anaplastic Lymphoma Kinase (ALK).
  • U.S. precision medicine market share accounted for over 65% of the North American revenue in 2015, and is anticipated to continue witnessing growth due to increased government initiatives. For instance, The President’s budget in 2016 has allocated USD 130 million to the NIH for development of a national research cohort of a million voluntary U.S. participants, and the data is linked to EHR for easy access to academic scientists and physicians.
  • China contributed 25% to the Asia Pacific precision medicine market size in 2015, mainly due to considerable government initiatives supporting growth in the region. Pfizer, Novartis, Covance, Medtronics, Qiagen, Quest Diagnostics, Roche Holding, Teva Pharmaceuticals, and Biocrates Life Sciences are some notable industry participants.

Global Market Insights has segmented the precision medicine industry on the basis of technology, application, and region:

  • Precision Medicine Market Technology Analysis (Revenue, USD Million; 2013 – 2023)
    • Big data analytics
    • Gene Sequencing
    • Drug discovery
    • Bio Informatics
    • Companion Diagnostics
  • Precision Medicine Market Application Analysis (Revenue, USD Million; 2013 – 2023)
    • Oncology
    • CNS
    • Immunology
    • Respiratory
  • Precision Medicine Market Regional Analysis (Revenue, USD Million; 2013 – 2023)
    • North America
      • U.S.
      • Canada
    • Europe
      • UK
      • Germany
      • France
      • Italy
      • Scandinavia
    • Asia Pacific
      • China
      • Japan
      • India
      • Singapore
    • Latin America
      • Mexico
      • Brazil
    • MEA
      • South Africa
      • Saudi Arabia
      • Qatar
      • UAE

SOURCE

From: Jui Kate <jui.k@gminsights.com>

Date: Friday, February 17, 2017 at 6:35 AM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: Article Publication Request

Read Full Post »


Personalized Medicine Meeting – Discussion on FDA Regulation with Outgoing FDA Commissioner, Pharma and Investors

Reporter: Aviva Lev-Ari, PhD, RN

The agency has long felt that the current oversight provided by the Centers for Medicare & Medicaid Services under CLIA has critical gaps and is putting patients at risk. However, for more than two decades, the lab industry has aggressively fought against FDA regulation by threatening legal action and lobbying Congress. Despite industry objections, the FDA two years ago pushed ahead a draft guidance outlining a risk-based oversight plan for LDTs. However, following the November elections, the agency said it would hold off on finalizing those plans in order to consider input from other groups and await further input from the new administration.

Then, a week before Donald Trump was sworn into office, the agency released a discussion paper outlining a revised regulatory framework for LDTs based on more than 300 comments to its draft guidance, a public workshop, and meetings with stakeholders. The paper allowed the agency, without issuing enforceable regulations, to publicly respond to the lab industry’s concerns about burdensome requirements, demonstrate that it had listened to critics of the draft plan, and lay out the rationale, once again, for why FDA needed to step in to look at aspects of test development that CMS doesn’t.

“I think the community better take this really seriously,” Califf said discussing LDT regulation at the PMWC. While on the one hand regulation shouldn’t stifle innovation, he noted that doctors can’t be left to figure out which test they should order. “We’ve got to come up with some middle ground, so regardless of where you are in the US you can get a reproducible laboratory result,” he said, especially when patients’ treatment decisions depend on those results. “I think that’s upcoming work for this year,” Califf added.

Some industry observers have noted that in a crowded immunotherapy market, the availability of multiple PD-L1 tests, the availabilty of FDA approved kits and unapproved LDTs that seemingly gauge the same analyte, and the companion versus complementary diagnostic categories, are actually confusing physicians. This has led to some to suggest that drugmakers work with regulators to advance one test.

Additional Sources

  • New Complementary Dx Category Provides Regulatory Flexibility, but Poses Real WorldChallenges

GenomeWeb , 2016

  • At CDx Harmonization Meeting, Drugmakers Take First Step Toward Exploring Test Differences

GenomeWeb , 2015

  • In Approving Opdivo With Dakos Complementary Test, FDA Advances Rx Personalization Option

GenomeWeb , 2015

  • In 2016, Personalized Medicine Saw More CDx Deals, Flexible FDA, No LDT Guidance

GenomeWeb , 2017

  • Agilents Dako Lands FDA Approval for Lung Cancer Complementary Dx

GenomeWeb , 2015

  • In 2015, Precision Medicine Options Grew; FDA, Labs Still at Odds; Payment Remained Mostly Elusive

GenomeWeb , 2015

Outgoing FDA Commissioner, Pharma, Investors Discuss Regulation at Personalized Medicine Meeting

Jan 24, 2017 | Turna Ray

SOURCE

https://www.genomeweb.com/molecular-diagnostics/outgoing-fda-commissioner-pharma-investors-discuss-regulation-personalized?utm_source=SilverpopMailing&utm_medium=email&utm_campaign=Daily%20News:%20NSF,%20USDA%20Award%20Microbiome%20Research%20Grants%20-%2001/24/2017%2004:15:00%20PM

Read Full Post »


Dr. Jennifer Doudna (UC Berkeley): PMWC 2017 Luminary Award, January 22, 2017 @PMWC 2017, January 23-25, Silicon Valley

Reporter: Aviva Lev-Ari, PhD, RN

 

 

PMWC will be honoring Dr. Jennifer Doudna (UC Berkeley) with the Luminary Award for spearheading the development of the groundbreaking Crispr-Cas9 genome editing technology

 

PMWC Interview with Dr. Jennifer Doudna (UC Berkeley)

http://www.pmwcintl.com/jennifer-doudna-qa/ 

Session Themes

http://www.pmwcintl.com/2017sv/program/sessions/

Event Registration

http://www.pmwcintl.com/2017sv/registration/

pmwc2017sv-logo

Luminary & Pioneer Awards

The PMWC Luminary Award recognizes recent contributions of preeminent figures who have accelerated personalized medicine into the clinical marketplace. The PMWC Pioneer Award is given to rare individuals who presaged the advent of personalized medicine when less evolved technology and encouragement from peers existed, but still made major advances in the field.

This year, PMWC will be honoring Dr. Jennifer Doudna (UC Berkeley) with the Luminary Award for spearheading the development of the groundbreaking Crispr-Cas9 genome editing technology and Edward F. Chang for developing advanced neurophysiologic brain mapping methods. For the Pioneer Award, Dr. James Allison (MD Anderson Cancer Center) will be recognized for pioneering cancer immunotherapy through his discovery of the immune checkpoint blockade. Dr. Stephen Quake (Stanford) will receive a Pioneer Award for his prolific inventions of technologies in microfluidics and genetics that have enabled personalized medicine, drug discovery and non-invasive diagnostics.

When: January 22, 2017 at 6:30-8:30pm

http://www.pmwcintl.com/2017sv/awards/ 

 

SOURCE

From: Tal Behar PMWC <talb=pmwcintl.com@mail29.atl161.mcsv.net> on behalf of Tal Behar PMWC <talb@pmwcintl.com>

Reply-To: Tal Behar PMWC <talb@pmwcintl.com>

Date: Tuesday, December 20, 2016 at 1:50 PM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: Largest Biotech Patent Case in History Will Determine Who Owns CRISPR

 

Other related articles published on CRISPR on this Open Access Online Scientific Journal include the following:

 

UPDATED – Status “Interference — Initial memorandum” – CRISPR/Cas9 – The Biotech Patent Fight of the Century: UC, Berkeley and Broad Institute @MIT

Reporter: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2016/01/06/status-interference-initial-memorandum-crisprcas9-the-biotech-patent-fight-of-the-century/

 

First CRISPR clinical trial gets green light from US panel – The technique’s first test in people could begin as early as the end of the year, 22 June 2016

Sara Reardon

http://www.nature.com/news/first-crispr-clinical-trial-gets-green-light-from-us-panel-1.20137

 

We Celebrate 5,000 Scientific Articles @pharmaceuticalintelligence.com – 2016 was a GREAT Year !!!!!

https://pharmaceuticalintelligence.com/2016/12/19/we-celebrate-5000-scientific-articles-pharmaceuticalintelligence-com-2016-was-a-great-year/

CRISPR – 124 articles on 12/20/2016

https://pharmaceuticalintelligence.com/category/crisprcas9-gene-editing/

Personalized Medicine and Precision Medicine and Genomics Research – 618 articles on 12/20/2016

https://pharmaceuticalintelligence.com/category/personalized-and-precision-medicine-genomic-research/

Contributions to Personalized and Precision Medicine & Genomic Research: Larry H. Bernstein, MD, FCAP 

https://pharmaceuticalintelligence.com/2016/02/19/contributions-to-personalized-and-precision-medicine-genomic-research-larry-h-bernstein-md-fcap/

 

Genomics Orientations for Personalized Medicine

on Amazon since 11/23/2015

http://www.amazon.com/dp/B018DHBUO6

Chapter 21 in this e-Book:

Advances in Gene Editing Technology: New Gene Therapy Options in Personalized Medicine – Medical Interpretation of the Genomics Frontier – CRISPR – Cas9

Chapter Curators: Larry H Bernstein, MD, FCAP, Stephen J Williams, PhD and Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/biomed-e-books/genomics-orientations-for-personalized-medicine/volume-one-genomics-orientations-for-personalized-medicine/
genomicsinpersonalizedmedicinecovervolumeone

Read Full Post »


LIVE Tweets via @pharma_BI and @AVIVA1950 for Presentations on 11/16 – 11/17, 2016, The 12th Annual Personalized Medicine Conference, HARVARD MEDICAL SCHOOL, Joseph B. Martin Conference Center, 77 Avenue Louis Pasteur, Boston

 

  1. Aviva Lev-Ari‏@AVIVA1950 Nov 17

#PMConf The 12th Annual Personalized Medicine Conference, GENOMICS data sharing initiatives https://pharmaceuticalintelligence.com/2016/11/17/live-1117-145pm-5pm-the-12th-annual-personalized-medicine-conference-harvard-medical-school-joseph-b-martin-conference-center-77-avenue-louis-pasteur-boston/ … via @Pharma_BI

 

  1. Aviva Lev-Ari‏@AVIVA1950 Nov 17

LIVE 11/17 1:45PM – 5PM – The 12th Annual Personalized Medicine Conference, HARVARD MEDICAL SCHOOL, … https://pharmaceuticalintelligence.com/2016/11/17/live-1117-145pm-5pm-the-12th-annual-personalized-medicine-conference-harvard-medical-school-joseph-b-martin-conference-center-77-avenue-louis-pasteur-boston/ … via @Pharma_BI

 

  1. Aviva Lev-Ari‏@AVIVA1950 Nov 17

#PMConf @pharma_BI Announcing: BROAD + Intel Center for Advanced Genomic Data Engineering, Anthony Philippakis, M.D., Ph.D.,Broad Institute

 

  1. Aviva Lev-Ari‏@AVIVA1950 Nov 17

#PMConf @pharma_BI My Research Legacy: Broad & AHA – Launched November 13, 2016 Anthony Philippakis, M.D., Ph.D., AMAZING mind among us

 

  1. Aviva Lev-Ari‏@AVIVA1950 Nov 17

3PMConf @pharma_BI Genetic component to become part of Patient care Recepient Leadership in Personalized Medicine Award, Raju Kucherlapati

 

  1. Aviva Lev-Ari‏@AVIVA1950 Nov 17

#PMConf @pharma_BI Kristine Bordenave, M.D., Lead Medical Director, Humana complex Clinical perspective, cost to patient, clinician, Pharma

  1. Aviva Lev-Ari‏@AVIVA1950 Nov 17

#PMConf @pharma_BI 25 of 50 States are participants in MOlDx — NOT New England State Elaine Jeter, M.D., MolDx Medical Director, Palmetto

 

  1. Aviva Lev-Ari‏@AVIVA1950 Nov 17

#PMConf @pharma_BI Richard Hamermesh, Harvard Bus School led GREAT Case Study Presentation on IP disputed DNA-editing technologies, CRISPR

 

9.  Aviva Lev-Ari ‏@AVIVA1950  Nov 17

#PMConf @pharma_BI 65,000 molecular tests in the market in the Registry only 10,000 Elaine Jeter, M.D., MolDx Medical Director, PalmettoGBA

10. Aviva Lev-Ari‏@AVIVA1950 Nov 17

@pharma_BI #PMConf Daniel O’Day, CEO, Roche Pharmaceuticals is Optimistic on Personalized Med – new US Gov’t – no change in Roche Mission

11. Aviva Lev-Ari‏@AVIVA1950  Nov 16

#PMConf Pricing Drugs and THerapeutic Outcomes, The 12th Annual Personalized Medicine Conference, HMS https://pharmaceuticalintelligence.com/2016/11/16/live-1116-315pm-530pm-the-12th-annual-personalized-medicine-conference-harvard-medical-school-joseph-b-martin-conference-center-77-avenue-louis-pasteur-boston/ … via @Pharma_BI

 

 

  1. Aviva Lev-Ari‏@AVIVA1950  Nov 16

#PMConf Molecular DIagnostics LIVE 11/16 1:15PM – 2:45PM – The 12th Annual PM Conference, https://pharmaceuticalintelligence.com/2016/11/16/live-1116-115pm-245pm-the-12th-annual-personalized-medicine-conference-harvard-medical-school-joseph-b-martin-conference-center-77-avenue-louis-pasteur-boston/ … via @Pharma_BI

 

  1. Aviva Lev-Ari‏@AVIVA1950  Nov 16

STAR @ #PMConf Eric Dishman, Director, All of Us Research Program, National Institutes of Health https://pharmaceuticalintelligence.com/2016/11/16/live-1116-8am-noon-the-12th-annual-personalized-medicine-conference-harvard-medical-school-joseph-b-martin-conference-center-77-avenue-louis-pasteur-boston/ … via @Pharma_BI

 

  1. Aviva Lev-Ari‏@AVIVA1950  Nov 16

@pharma_BI @AVIVA1950 #PMConf LIVE Personalized Medicine Conference, HARVARD MEDICAL SCHOOL, Jose… https://pharmaceuticalintelligence.com/2016/11/16/live-1116-8am-noon-the-12th-annual-personalized-medicine-conference-harvard-medical-school-joseph-b-martin-conference-center-77-avenue-louis-pasteur-boston/ … via @Pharma_BI

 

  1. Aviva Lev-Ari‏@AVIVA1950  Nov 16

#PMConf @pharma_BI @AVIVA1950 covering in REAL TIME 12th Annual @PartnersPersMed at Harvard Medical School @harvardmed today + tomorrow

 

 

 

Read Full Post »


Real Time Coverage and eProceedings of Presentations on 11/16 – 11/17, 2016, The 12th Annual Personalized Medicine Conference, HARVARD MEDICAL SCHOOL, Joseph B. Martin Conference Center, 77 Avenue Louis Pasteur, Boston

 

LIVE 11/16 8AM – noon The 12th Annual Personalized Medicine Conference, HARVARD MEDICAL SCHOOL, Joseph B. Martin Conference Center, 77 Avenue Louis Pasteur, Boston

https://pharmaceuticalintelligence.com/2016/11/16/live-1116-8am-noon-the-12th-annual-personalized-medicine-conference-harvard-medical-school-joseph-b-martin-conference-center-77-avenue-louis-pasteur-boston/

 

LIVE 11/16 1:15PM – 2:45PM – The 12th Annual Personalized Medicine Conference, HARVARD MEDICAL SCHOOL, Joseph B. Martin Conference Center, 77 Avenue Louis Pasteur, Boston

https://pharmaceuticalintelligence.com/2016/11/16/live-1116-115pm-245pm-the-12th-annual-personalized-medicine-conference-harvard-medical-school-joseph-b-martin-conference-center-77-avenue-louis-pasteur-boston/

 

LIVE 11/16 3:15PM – 5:30PM – The 12th Annual Personalized Medicine Conference, HARVARD MEDICAL SCHOOL, Joseph B. Martin Conference Center, 77 Avenue Louis Pasteur, Boston

https://pharmaceuticalintelligence.com/2016/11/16/live-1116-315pm-530pm-the-12th-annual-personalized-medicine-conference-harvard-medical-school-joseph-b-martin-conference-center-77-avenue-louis-pasteur-boston/

 

LIVE 11/17 8AM – 1:45PM – The 12th Annual Personalized Medicine Conference, HARVARD MEDICAL SCHOOL, Joseph B. Martin Conference Center, 77 Avenue Louis Pasteur, Boston

https://pharmaceuticalintelligence.com/2016/11/17/live-1117-8am-145pm-the-12th-annual-personalized-medicine-conference-harvard-medical-school-joseph-b-martin-conference-center-77-avenue-louis-pasteur-boston/

 

LIVE 11/17 1:45PM – 5PM – The 12th Annual Personalized Medicine Conference, HARVARD MEDICAL SCHOOL, Joseph B. Martin Conference Center, 77 Avenue Louis Pasteur, Boston

https://pharmaceuticalintelligence.com/2016/11/17/live-1117-145pm-5pm-the-12th-annual-personalized-medicine-conference-harvard-medical-school-joseph-b-martin-conference-center-77-avenue-louis-pasteur-boston/

 

Read Full Post »


LIVE 11/17 1:45PM – 5PM – The 12th Annual Personalized Medicine Conference, HARVARD MEDICAL SCHOOL, Joseph B. Martin Conference Center, 77 Avenue Louis Pasteur, Boston

 

Leaders in Pharmaceutical Business intelligence (LPBI) Group

Covering in Real Time using Social Media this Event on

Personalized Medicine

Aviva Lev-Ari, PhD, RN, Founder LPBI Group & Editor-in-Chief

http://pharmaceuticalintelligence.com

Streaming LIVE @ HARVARD MEDICAL SCHOOL,

Joseph B. Martin Conference Center

@pharma_BI

@AVIVA1950

November 17

#PMConf

1:45 p.m. — Leadership in Personalized Medicine Award

  • Presenter: William S. Dalton, Ph.D., M.D., CEO, M2Gen, Chairman, Personalized Medicine Coalition

Science, Business and Patents: Millenium, Celgenics, and Medicine/Desease – Member of AAAS

co-Chair Cancer Consorcium

PM – 1990’s on. How Human Genome at Harvard will start a new center – reach out to the Global community, conference was born. PM as subject of a Global Conference, effirt started with Genzyme, Eric Launder, Broad, Collins at NIH – effort led to Obama Initiative in PM, Duke Medical System.

Challenge: Reimbursement for Genomics diagnosis

  • PM – P care – by sequencing of Genome – become available commercially inexpensivelly
  • Genetic component to become part and parcial of Medicine and Patient care

2:15 p.m. — Networking Break

2:45 p.m. — The Data Dilemma: Fulfilling Expectations of Big Data in the Future of Personalized Medicine

There is consensus that the massive amounts of genomic, clinical, claims and other types of data could yield important insights for research and clinical care. But for years, obstacles around technical standards, interoperability, privacy and confidentiality, data security, and consent have been held up as daunting challenges that inevitably slowed progress.  During this discussion, a panel of academic and industry experts will discuss their respective organizations’ strategies to obtain and analyze the data, including what has worked and what has not; the programs and processes that have led to the most productive data usage; examples of important knowledge that has been derived from data analysis; and the infrastructure they believe is needed to achieve fulfillment of the potential of big data in personalized medicine nationwide.

  • Moderator: Marcia A. Kean, M.B.A., Chairman, Strategic Initiatives, Feinstein Kean Healthcare
  1. How one works with 20 Partners at once?

 

  • Paul Bleicher, M.D., Ph.D., CEO, OptumLabs
  1. Data collaboration of 35 Partners – bring value to Medicine, Like Bell Labs
  2. Academics, Hospitals, Physician offices – Constellations – groups of projects
  3. DATA is KEY — Public and Private Partnerships
  • Christophe G. Lambert, Ph.D., Associate Professor, Center for Global Health, Division of Translational Informatics, Department of Internal Medicine, University of New Mexico
  1. VA Data, Co-Chair of Informatics, clinical , pharmaceutical stackholders
  2. Focus Groups Patient research Partners – How to automate data
  3. Centralization above nad decentralization, below COntrol mechanism govern all variables: Increase fitness of system vs Personal Control
  4. 1984-1998 Bi-Partisan support for Data in HealthCare
  5. Big Data for early detection, prevention, `
  6. AGING, Infectious and Pediatric disease – Investment in these areas
  • Adam Margolin, Ph.D., Director, Computational Biology, Oregon Health & Science University School of Medicine
  1. Project with Intel – across institutions
  2. consorsium – success ration
  3. data sharing #1 Priority at the National Level
  4. Add value by data sharing, strategic investment in the healh system
  • Edward J. Stepanski, Ph.D., Chief Operating Officer, Vector Oncology
  1. Propriatory real time reporting to Physicians – systematic – core asset, originally,
  2. Research Group use Warehouse doing Analytics, Tools development linked with clinical data with PRO and studies based on data integretion
  3. Success is more data – PRO data informing clinical data
  4. Defragmenting the care vs drive across town for care several units disaggregated geography vs all deaprtments in one location

 

3:45 p.m. — Keynote Speaker
“Medicine and the Targeted Marketing Problem”

We live in the golden age of cloud computing and machine learning.  The organizing conundrum for the “big data era,” however, is a surprising one — the “targeted marketing problem” (i.e., the ability to better match the right customers to targeted messages). This talk will explore overlaps and similarities between the targeted marketing problem and precision medicine, and how advances in data sciences can be leveraged to create a learning medical system that in turn points to the health care system of the future.

  • Introduction: Amy Abernethy, M.D., Ph.D., Chief Scientific Officer, Senior Vice President, Oncology, Flatiron Health

 

  • Anthony Philippakis, M.D., Ph.D., Cardiologist, BWH, Chief Data Officer, Broad Institute and Partner, GV (Venture Capital)

Learning from Users

Five causes for cardiac death:

  • MI,
  • a-Fib
  • Structural
  • PE
  • Aorta dissection

PreventionGenomic Sequencingvalue in Cardiology:

  • Estonia BioBank – mutation carrier
  • Familial Hypercholesterolemia – 4 genes involved,
  • Prediction sudden cardiac death – larger data sets
  • New Model for Human Subjects Research; DIrect-to-Participant: Potentia Advantages:
  • cost, scalability, facilitate re-contact, frequent collection,
  • My Research Legacy: Broad & AHA – Launched November 13, 2016 
  • Quantified Self –>> Quantigied Physical Exam: Face dysformia, Dysarthia, Ataxia,
  • Identify every patient in the World  with this disease

 

Data sharing: Inverting the Model ; ALL OF US  – 1 Million – Precision Medicine with IBM – Mandate to innovate – Diversity: People, Geography, Health Status

Innovation in Genomic data sharing – bring data to researchers

SIX types od data wil be collected: Participant-provided Info, mHealth Data, Consent EMR

 

DATA Research CoreVanderbuilt, Verily Broad

  1. pharmacogenomics

Launch start ups cost

  1. Open source
  2. Cloud
  3. developers start ups

PLATFORM

 

GATK – workhorse of genomic data – Launched 4/2016

Partnerships: Amazon, google genomics, microsoft, IBM, Watson, 

 

Announcing: BROAD + Intel Center for Advanced Genomic Data Engineering, Anthony Philippakis, M.D., Ph.D., Chief Data Officer, Broad Institute

Reference Architecture: Design: Single node, small cluster,

 

4:30 p.m. — Closing Remarks

  • Edward Abrahams, Ph.D., President, Personalized Medicine Coalition

 

– See more at: http://www.personalizedmedicinecoalition.org/Conference/November_17_Program#sthash.zpTNQYKd.dpuf

 

#PMConf

SOURCE

http://www.personalizedmedicinecoalition.org/Conference/November_17_Program

Read Full Post »

Older Posts »